摘要
目的探讨基质金属蛋白酶3(MMP-3)启动子区域-1612位点5A/6A(MMP-316125A/6A)基因多态性与阿托伐他汀治疗颈动脉粥样硬化疗效的相关性。方法选取医院2018年1月至12月收治的经颈动脉彩超检查发现颈动脉斑块的患者54例。治疗前,经聚合酶链式反应-限制性片段长度多态性(PCR-RFLP)法检测患者MMP-316125A/6A基因位点多态性(6A/6A,5A/6A,5A/5A),并检测总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、MMP-3水平。所有患者均予阿托伐他汀治疗。于治疗6个月、12个月后复查血脂、MMP-3水平及颈动脉彩超以评估疗效。结果治疗12个月后,与初诊时比较,3种基因型患者的TC,TG,LDL-C水平均显著降低,HDL-C水平均显著升高(P<0.05或P<0.01);治疗前后,各基因型患者组间的TC,TG,LDL-C,HDL-C水平比较,差异均无统计学意义(P>0.05)。与初诊比较,各组基因型患者治疗6个月、12个月后,MMP-3水平、颈动脉斑块积分均显著降低(P<0.05);初诊及治疗6个月后,各组基因型患者组间MMP-3水平、颈动脉斑块积分均无显著差异(P>0.05);治疗12个月后,5A/5A基因型患者MMP-3水平、颈动脉斑块积分均显著低于6A/6A基因型及5A/6A基因型患者(P<0.05)。结论阿托伐他汀可有效降低MMP-316125A/6A 3种基因型患者的颈动脉斑块积分;除通过调脂作用外,阿托伐他汀还可能通过降低MMP-3水平改善MMP-316125A/5A基因型患者的颈动脉粥样硬化。
Objective To investigate the correlation between matrix metalloproteinase-3(MMP-3)gene(-16125 A/6 A)polymorphism and the efficacy of atorvastatin in the treatment of carotid atherosclerosis.Methods A total of 54 patients with carotid plaques diagnosed by carotid color Doppler ultrasound in our hospital from January to December 2018 were selected.Before treatment,the polymorphism(6 A/6 A,5 A/6 A,5 A/5 A)of MMP-316125 A/6 A gene locus of the patients was detected by PCR/RFLP,and the levels of total cholesterol(TC),triglyceride(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)and MMP-3 were detected.All patients were treated with atorvastatin.After six months and twelve months of treatment,the levels of blood lipid and MMP-3,and the carotid artery color Doppler ultrasound were reexamined to evaluate the efficacy.Results After twelve months of treatment,the levels of TC,TG and LDL-C decreased,while the level of HDL-C increased in patients with three genotypes compared with those at the time of initial diagnosis(P<0.05 or P<0.01).Before and after treatment,there was no statistically significant difference in the levels of TC,TG,LDL-C,HDL-C among the groups of patients with different genotypes(P>0.05).After six months and twelve months of treatment,the groups of patients with different genotypes had statistically significant differences in the levels of MMP-3 and the scores of carotid plaque compared with those at the time of initial diagnosis(P<0.05).At the time of initial diagnosis and after six months of treatment,there was no statistically significant difference in the levels of MMP-3 and the scores of carotid plaque among the groups of patients with different genotypes(P>0.05).After twelve months of treatment,the levels of MMP-3 and the scores of carotid plaque of patients with 5 A/5 A genotype were significantly lower than those of patients with 6 A/6 A and 5 A/6 A genotypes(P<0.05).Conclusion Atorvastatin can effectively reduce the scores of carotid plaque in patients with three genotypes of MMP-316125 A/6 A.In addition to the lipid-lowering effect,atorvastatin may also improve carotid atherosclerosis in patients with MMP-316125 A/5 A genotype by reducing the levels of MMP-3.
作者
吴仕平
刘青
WU Shiping;LIU Qing(Department of Geriatrics,Suining Central Hospital,Suining,Sichuan,China 629000)
出处
《中国药业》
CAS
2021年第9期46-49,共4页
China Pharmaceuticals
基金
四川省软科学研究计划项目[2017ZR0052]。
